Arcutis Biotherapeutics (NASDAQ:ARQT) Upgraded by Mizuho to Buy
Mizuho upgraded shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) from a neutral rating to a buy rating in a research report report published on Tuesday morning, Marketbeat.com reports. The firm currently has $8.00 price objective on the stock, up from their prior price objective of $4.00. Several other research firms have also recently issued […]
More Stories
Speaker Johnson Says Budget Bill Act Won’t Trigger More Federal Spending
By Jack Phillips House Speaker Mike Johnson (R-La.) said that the budget bill endorsed by President Donald Trump that passed...
Messi’s Late Free Kick Goal Sparks Inter Miami to Rally for a 3–3 Tie Against Union
By The Associated Press CHESTER, Pa.—Lionel Messi gave Inter Miami a pep talk this week, exhorting his MLS team to...
Key Vote Puts Texas Closer to Displaying Ten Commandments in Classrooms
By Jacob Burg The Texas Legislature cleared a major vote on May 24 on a measure that would require the...
Amazon.com, Inc. (NASDAQ:AMZN) is Concorde Financial Corp’s 6th Largest Position
Concorde Financial Corp lifted its position in Amazon.com, Inc. (NASDAQ:AMZN) by 0.3% in the 4th quarter, HoldingsChannel reports. The firm...
Crow s Nest Holdings LP Decreases Stock Holdings in Amazon.com, Inc. (NASDAQ:AMZN)
Crow s Nest Holdings LP cut its holdings in Amazon.com, Inc. (NASDAQ:AMZN) by 19.1% during the fourth quarter, according to...
Amazon.com, Inc. (NASDAQ:AMZN) Shares Sold by Concentric Capital Strategies LP
Concentric Capital Strategies LP lowered its position in shares of Amazon.com, Inc. (NASDAQ:AMZN) by 33.1% in the fourth quarter, according...